Coverage
— → Added to coverage
Current stock research snapshot · Not reviewed Date unavailable
ALNYAlnylam Pharmaceuticals
Investment conviction●●●○○3 of 5 · current snapshot
Research target—Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$31.73BSnapshot value · Not reviewed
Research history
See all ALNY changes ↗What changed
Leading clinically-validated RNAi delivery platform (GalNAc liver targeting). Converts chronic dosing into infrequent (biannual) administration for cardiometabolic prevention — PCSK9, Lp(a) (zilebesiran), APOC3, ANGPTL3, TTR. Platform economics via partnerships. Demand engine feeding the Manufacture/Package & Deliver toll-road stack, not a toll-road itself.
Zilebesiran Lp(a) Phase 2/3 progression (partnered); APOC3 + hypertension programs; expansion from rare disease to population-scale cardiometabolic prevention; infrequent-dosing label wins.
Lp(a) outcomes trials fail or biomarker lowering does not translate to event reduction; in-vivo gene editing (NTLA/BEAM/VERV) becomes an economically superior one-time substitute; extrahepatic delivery unsolved capping TAM; prevention pricing/reimbursement pressure.
No social-sentiment snapshot available.
Snapshot · Not reviewed🟡 Mixed · ins-$2.1M · 13F 18+/7-×0.5 · short↑0.38
Snapshot · Not reviewed